In this first-ever collaboration between Communicable and Breakpoints, the podcast of the US Society of Infectious Diseases Pharmacists, hosts Angela Huttner (Geneva, Switzerland) and Erin McCreary (Pittsburgh, USA) join trial investigators Josh Davis (Newcastle, Australia) and Steven Tong (Melbourne, Australia) to unpack the first results coming from the SNAP adaptive platform trial, which were recently presented at ESCMID Global in Vienna. Learn whether penicillin and cefazolin are non-inferior to—and maybe even safer than—flucloxacillin for penicillin-susceptible and methicillin-susceptible Staphylococcus aureus, respectively.This episode was edited by Julie Anne Justo, transcribed by Katie Lambert and Sarah Groome, and peer-reviewed by Megan Klatt and Lacy Worden. Communicable and Breakpoints released this episode on 5 May 2025.Declaration of competing interestS.Y.C.T. has served on an advisory board for AstraZeneca for a staphylococcal monoclonal antibody programme and receives royalties from UpToDate for editing S. aureus–related content. E.K.M. has previously served on scientific advisory boards for the following pharmaceutical companies: Abbvie, Basilea, Melinta, GSK, and serves on the DSMC for the SNAP trial. Other authors declare no financial interests/personal relationships that may be considered as potential competing interests. Note on conflict of interest for SNAP Data Safety Monitoring Committee (DSMC) members:Conflicts of interest were evaluated when choosing individuals to serve on the SNAP DSMC. Aside from being compensated for their duties on the committee, DSMC members have no ongoing financial relationships that relate to the trial and are not involved in the conduct of the trial in any role other than that of a DSMC member. DSMC members have no intellectual conflict of interest or bias and reviewed SNAP data in a fully objective manner.Related podcast episodeCommunicable Episode 26: SNAP out of it - the SNAP trial PSSA/MSSA results https://share.transistor.fm/s/2a3c3bb4Further reading[1]Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603–61. DOI:https://doi.org/10.1128/CMR.00134-14.[2]SNAP Adaptive trial platform/results of the PSSA & MSSA domains:• https://www.snaptrial.com.au/ESCMID Global April 2025 presentation:• www.online.escmid.org *• https://www.escmid.org/congress-events/escmid-global/programme/scientific-programme/[3]CloCeBa trial results (ESCMID Global April 2025 presentation):• www.online.escmid.org *• https://www.escmid.org/congress-events/escmid-global/programme/scientific-programme/[4]CAMERA 2 trial; Tong SY, Lye DC, Yahav D, et al. Without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323(6):527–37. DOI:https://doi.org/10.1001/jama.2020.0103.[5]POET trial; Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380:415–24. DOI:https://doi.org/10.1056/NEJMoa1808312.[6]POET trial follow-up: Pries-Heje MM, Wiingaard C, Ihlemann N. Five-year outcomes of the partial oral treatment of endocarditis (POET) trial. N Engl J Med. 2022;386:601–02. DOI:https://doi.org/10.1056/NEJMc2114046.*Note on access to online video of ESCMID Global presentations:•In the six months following the congress:• Non-ESCMID members have access if they registered for ESCMID Global• Members have access only if they registered for ESCMID Global•Six months after the congress:• Non-members do not have access, whatever their ESCMID Global registration status• All members have access, whatever their ESCMID Global registration status

It’s World AMR Awareness Week (WAAW) and we have prepared a special...

Take this survey powered by surveymonkey.com. Create your own surveys for free.

In this episode of Communicable, Erin McCreary and Angela Huttner are...

Social media is a cultural and communications phenomenon that is an integral part of life in the 2020s. Twitter was founded in 2006 and became a leading social media platform with an active user base ...

ALT: a cartoon penguin reading a newspaper with the words good news written above it

Contrary to popular belief, peer review has only recently become an...